HC Wainwright Forecasts Genelux’s Q1 Earnings (NASDAQ:GNLX)

Genelux Co. (NASDAQ:GNLX) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Genelux in a research report issued to clients and investors on Tuesday, March 25th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($0.16) per share for the quarter. HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.22) EPS and FY2029 earnings at $2.58 EPS.

Genelux Stock Performance

Shares of NASDAQ GNLX opened at $3.03 on Wednesday. Genelux has a 52 week low of $1.60 and a 52 week high of $6.50. The stock’s fifty day moving average is $4.05 and its 200 day moving average is $3.09. The stock has a market capitalization of $104.65 million, a P/E ratio of -3.19 and a beta of -1.41.

Hedge Funds Weigh In On Genelux

Several hedge funds have recently bought and sold shares of the company. Brown Brothers Harriman & Co. boosted its position in shares of Genelux by 76.2% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock worth $50,000 after acquiring an additional 9,114 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Genelux in the 3rd quarter valued at $59,000. Geode Capital Management LLC increased its stake in shares of Genelux by 39.7% in the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock valued at $749,000 after purchasing an additional 89,854 shares during the last quarter. Apollon Wealth Management LLC raised its holdings in shares of Genelux by 20.4% during the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock worth $40,000 after buying an additional 2,857 shares in the last quarter. Finally, D.A. Davidson & CO. bought a new stake in shares of Genelux during the 4th quarter worth $51,000. 37.33% of the stock is owned by institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.